The Lancet Neurology最新文献

{"title":"Correction to Lancet Neurol 2025; 24: 481","authors":"","doi":"10.1016/s1474-4422(25)00202-9","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00202-9","url":null,"abstract":"<em>Villain N, Frisoni GB, Feldman HH, Dubo B. The International Working Group recommendations on cognitively unimpaired individuals.</em> Lancet Neurol <em>2025; <strong>24:</strong> 481</em>—In this Correspondence, the spelling of the author Giovanni Frisoni's name was incorrect. Also, a declaration on the use of AI has been added to the manuscript. These corrections have been made to the online version as of June 17, 2025.","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatric traumatic brain injury: bridging evidence and care","authors":"Rebekah Mannix, Shruti Agrawal, Vicki Anderson, Miriam H Beauchamp, Adam R Ferguson, Lucia Willadino Braga, Shu-Ling Chong, Anthony Figaji, Christopher Giza, David K Menon, Michael J Bell","doi":"10.1016/s1474-4422(25)00206-6","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00206-6","url":null,"abstract":"No Abstract","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of blood pressure lowering in relation to time in acute intracerebral haemorrhage: a pooled analysis of the four INTERACT trials","authors":"Xia Wang, Xinwen Ren, Qiang Li, Menglu Ouyang, Chen Chen, Candice Delcourt, Xiaoying Chen, Jiguang Wang, Thompson Robinson, Hisatomi Arima, Lu Ma, Xin Hu, Chao You, Gang Li, Yang Jie, Yapeng Lin, Laurent Billot, Paula Muñoz-Venturelli, Sheila Martins, Octavio Marques Pontes-Neto, Craig S Anderson","doi":"10.1016/s1474-4422(25)00160-7","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00160-7","url":null,"abstract":"&lt;h3&gt;Background&lt;/h3&gt;Uncertainty remains about the effects of intensive blood pressure (BP) lowering in acute intracerebral haemorrhage, particularly the impact of treatment timing. This study aimed to assess the safety and effectiveness of early intensive BP-lowering treatment and its dependence on timing in patients with intracerebral haemorrhage.&lt;h3&gt;Methods&lt;/h3&gt;We undertook an individual patient-data pooled analysis of the four Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trials: INTERACT1 (n=404), INTERACT2 (n=2829), INTERACT3 (n=7036), and INTERACT4 (n=1043). INTERACT1–3 included adults with acute intracerebral haemorrhage who presented within 6 h of the onset of symptoms and had an elevated systolic BP (&gt;150 mm Hg). INTERACT4 included patients with suspected acute stroke that caused a motor deficit and an elevated systolic BP (≥150 mm Hg) within 2 h after the onset of symptoms, among whom 1029 had a haemorrhagic form of stroke. Patients were randomly assigned to receive intensive (target systolic BP &lt;140 mm Hg within 1 h) or guideline-recommended (target systolic BP &lt;180 mm Hg within 1 h) BP-lowering treatment using locally available drugs. The primary outcome was functional recovery, defined by the distribution of scores on the modified Rankin scale (mRS). In a CT substudy, radiological outcomes were relative (≥33%) and absolute (≥6 mL) changes in haematoma volume from baseline to 24 h. The treatment effects were determined in logistic regression models adjusting for trial and baseline haematoma volume. Heterogeneity in the effects across groups by time from onset to randomisation (continuous) and baseline severity according to the intracerebral haemorrhage score were assessed by adding interaction terms to the models. These trials are registered at &lt;span&gt;&lt;span&gt;ClinicalTrials.gov&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt; (INTERACT1 &lt;span&gt;&lt;span&gt;NCT00226096&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;; INTERACT2 &lt;span&gt;&lt;span&gt;NCT00716079&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;; INTERACT3 &lt;span&gt;&lt;span&gt;NCT03209258&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"&gt;&lt;/path&gt;&lt;/svg&gt;&lt;/span&gt;; INTERACT4 &lt;span&gt;&lt;span&gt;NCT03790800&lt;/span&gt;&lt;svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"&gt;&lt;path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"93 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unlocking the full clinical potential of the α-synuclein seed amplification assay","authors":"Lucilla Parnetti, Giovanni Bellomo, Lorenzo Gaetani","doi":"10.1016/s1474-4422(25)00204-2","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00204-2","url":null,"abstract":"No Abstract","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study","authors":"Shorena Janelidze, Lyduine E Collij, Niklas Mattsson-Carlgren, Alex Antill, Charles M Laymon, Ira Lott, H Diana Rosas, Davneet S Minhas, Weiquan Luo, Shahid Zaman, Mark Mapstone, Elizabeth Head, Florence Lai, Sigan L Hartley, Beau M Ances, Sharon J Krinsky-McHale, Joseph H Lee, Rik Ossenkoppele, Bradley T Christian, Oskar Hansson","doi":"10.1016/s1474-4422(25)00158-9","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00158-9","url":null,"abstract":"<h3>Background</h3>Plasma biomarkers associated with Alzheimer's disease could improve prognostic assessment for people with Down syndrome in both clinical practice and research settings. We aimed to identify the plasma biomarkers that most accurately predict longitudinal changes in Alzheimer's disease-related pathology and cognitive functioning in individuals with Down syndrome.<h3>Methods</h3>This longitudinal cohort study included data from 258 adults (aged ≥25 years) with Down syndrome who were followed up prospectively every 16 months as part of the longitudinal Alzheimer's Biomarker Consortium–Down Syndrome study (recruited from seven university sites in the USA and UK between July 13, 2016, and Jan 15, 2019). Participants had baseline and longitudinal assessments of plasma tau phosphorylated at threonine 217 (p-tau217), glial fibrillary acidic protein (GFAP), amyloid β (Aβ)_42/40, neurofilament light (NfL), or total tau (t-tau). Associations of baseline plasma biomarkers and longitudinal changes in plasma biomarkers with changes in global cognitive functioning (Down Syndrome Mental Status Examination [DS-MSE] scores), Aβ-PET, and tau-PET were examined using linear regression models. Plasma biomarker-associated risk of progression to dementia was assessed using Cox regression analysis.<h3>Findings</h3>Baseline p-tau217, as well as GFAP, NfL, or t-tau, were individually associated with longitudinal changes in DS-MSE, Aβ-PET, and tau-PET, and with progression to dementia. However, in combined models, only baseline p-tau217 remained associated with changes in DS-MSE (β –0·30 [95% CI –0·45 to –0·15], p=0·0001, n=220), tau-PET (0·42 [0·14 to 0·70], p=0·0039, n=88), and progression to dementia (hazard ratio 3·51 [95% CI 1·76–7·00], p=0·0004, n=194), whereas baseline p-tau217 (0·29 [0·14–0·45], p=0·0003) and GFAP (0·37 [0·18–0·56], p=0·0003) were associated with changes in Aβ-PET (n=106 for both). Similar associations were shown between longitudinal p-tau217 or GFAP and changes in DS-MSE (p-tau217: β –0·33 [95% CI–0·52 to –0·13], p=0·0015, n=133), tau-PET (p-tau217: 0·61 [0·40 to 0·83], p&lt;0·0001, n=87), and Aβ-PET (p-tau217: 0·35 [0·19 to 0·50], p&lt;0·0001; GFAP: 0·49 [0·27 to 0·70], p&lt;0·0001, n=88).<h3>Interpretation</h3>Baseline and longitudinal plasma p-tau217 were associated with subsequent decline in global cognition, progression to dementia, and increased tau burden, whereas baseline p-tau217 and GFAP were associated with Aβ accumulation. These findings suggest that plasma p-tau217 and GFAP might be valuable for prognostic assessment of Alzheimer's disease in people with Down syndrome in both clinical and research contexts. The results further support evaluation of these biomarkers for monitoring disease progression in clinical trials of Down syndrome-related Alzheimer's disease.<h3>Funding</h3>The European Research Council and National Institute on Aging (National Institute of Health).","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Honouring the amyotrophic lateral sclerosis research pledge","authors":"","doi":"10.1016/s1474-4422(25)00166-8","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00166-8","url":null,"abstract":"No Abstract","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144236981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective genetic variants against Alzheimer's disease","authors":"Claudia Marino, Vincent Malotaux, Averi Giudicessi, David Aguillon, Diego Sepulveda-Falla, Francisco Lopera, Yakeel T Quiroz","doi":"10.1016/s1474-4422(25)00116-4","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00116-4","url":null,"abstract":"Genetic studies can offer powerful insights for the development of disease-modifying therapies for Alzheimer's disease. Protective genetic variants that delay the onset of cognitive impairment have been found in people with sporadic Alzheimer's disease and in carriers of mutations that usually cause autosomal-dominant Alzheimer's disease in mid-life. The study of families who carry autosomal dominant mutations provides a unique opportunity to uncover genetic modifiers of disease progression, including rare variants in genes such as <em>APOE</em> and <em>RELN</em>. Understanding how these variants confer protection can help identify the biological pathways that contribute to cognitive resilience, such as the heparan-sulphate proteoglycan–APOE receptor pathway, the TREM-2-driven signalling pathways in the microglia, and phagocytosis. Therapies able to replicate the beneficial effects of these natural defences could provide novel strategies for slowing or preventing the progression of Alzheimer's disease.","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"195 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural neuroscience: rethinking brain research beyond the lab | Nachum Ulanovsky, Natural Neuroscience: Toward a Systems Neuroscience of Natural Behaviors, The MIT Press (2025), p. 302, ISBN: 978-0262044998","authors":"Vijay Shankar Balakrishnan","doi":"10.1016/s1474-4422(25)00171-1","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00171-1","url":null,"abstract":"No Abstract","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"32 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144103918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endovascular treatment of distal arterial occlusions: a more distant reality than ever?","authors":"Raul G Nogueira, Nirav Bhatt, Diogo C Haussen, Markus A Moehlenbruch, Thanh N Nguyen, Wei Hu","doi":"10.1016/s1474-4422(25)00128-0","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00128-0","url":null,"abstract":"No Abstract","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144104102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The future of gene therapy for Parkinson's disease","authors":"Roger A Barker, Philip C Buttery","doi":"10.1016/s1474-4422(25)00163-2","DOIUrl":"https://doi.org/10.1016/s1474-4422(25)00163-2","url":null,"abstract":"No Abstract","PeriodicalId":22676,"journal":{"name":"The Lancet Neurology","volume":"97 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144104179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}